Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients

International Journal of Cancer

Volumn 114, Issue 6, 2005, Pages 936-941

  Letsch, Anne ^a   Keilholz, Ulrich ^a   Fluck, Michael ^b   Nagorsen, Dirk ^a   Asemissen, Anne Marie ^a   Schmittel, Alexander ^a   Thiel, Eckhard ^a   Scheibenbogen, Carmen ^a  

^a Hematol Oncol and Transfus Med   (Germany)

^b Fachklinik Hornheide   (Germany)

Author keywords

Adjuvant; Immune monitoring; T cells

Indexed keywords

CANCER VACCINE; CHLORAMBUCIL; HYDROXYUREA; IMIDAZOLECARBOXAMIDE; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN 3; PEPTIDE DERIVATIVE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TYROSINASE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTESTINE CANCER; INTESTINE SURGERY; MALE; MELANOMA; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; SMALL INTESTINE; VACCINATION; VISCERAL METASTASIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CANCER VACCINES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RISK FACTORS; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, SUBUNIT;

EID: 17044440353     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20819     Document Type: Article

References (22)

1. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
2. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
3. Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jaeger D, Ilsemann, C, Hagedorn M, Oesch F, Knuth A. GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62.
4. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/melan A. Cancer J Sci Am 1996;3:37-44.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al. Immunologic and therapeutic evaluation of asynthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
6. + T cell frequencies by the ELISPOT assay in healthy individuals and patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000;87:391-8.
7. Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, Thiel E, Schadendorf D. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma. J Immunother 2000;23:275-81.
8. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186-200.
9. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffrey G, Marty V, Groshen S, Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
10. Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, et al. Phase I trial of a melanoma vaccine with gp100 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome. Clin Cancer Res 2001;7:3012-24.
11. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of IL-12 on the immune response to a multipeptide vaccine for resected melanoma. J Clin Oncol 2001;19:3836-47.
12. Scheibenbogen C, Nagorsen N, Seliger B, Schmittel A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Long-term freedom from recurrence in two high-risk melanoma patients following adjuvant vaccination with tyrosinase peptides. Int J Cancer 2001;99:403-8.
13. Scheibenbogen C, Schadendorf D, Bechrakis N, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U. Effects of GM-CSF and foreign helper protein as immunological adjuvants on the T cell response to vaccination with tyrosinase peptides. Int J Cancer 2003;104:188-94.
14. + memory T cells. Cancer Res 2003;63:5582-6.
15. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003;104:188-94.
16. + T cells in patients with advanced melanoma. Int J Cancer 2000;87:659-64.
17. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002;29:5-11.
18. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-7.
19. Keilholz U, Scheibenbogen C, Stoelben E, Saeger H, Hunstein W. Immunotherapy of metastatic melanoma with IFNa and IL-2: pattern of progression in responders and patients with stable disease without or with resection of residual lesions. Eur J Cancer 1994;30:955-8.
20. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Lienard D, Enk A, Dummer R, Hantich B, Geueke AM, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88.
21. Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C. CCR9 expression on melanoma cell lines is associated with small intestine metastases. J Invest Dermatol 2004;122:685-90.
22. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, Ward RL, Woodland DL, Lefrancois L. Activated primary and memory CD8 T cells migrate to nonlymphoid tissue regardless of site of activation or tissue of origin. J Immunol 2004;172:4875-82.